Biodesix

Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.

The year saw the launch of high-profile platforms as well as efforts by a number of parties to streamline mass spec technologies for the clinic.

In data presented at the ESMO annual meeting, the test showed some ability to distinguish between patients who responded to nivolumab and those who did not.

The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.

The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.

The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.

Biodesix will work with university researchers on an assay to help identify non-small cell lung cancer patients likely to respond to certain immunotherapies.

While the company has historically marketed the test's ability to predict patient drug response, it has more recently focused on its prognostic power.

The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.

GeneStrat is a blood-based test using a droplet digital PCR platform that detects mutations relevant to patient treatment in non-small cell lung cancer.

Pages